Ocular Therapeutix doses first wet-AMD patient in implant trial

Ocular Therapeutix doses first wet-AMD patient in implant trial

Submitted by admin on February 20, 2019 - 6:11pm
Source: 
Drug Delivery Business News
News Tags: 
Ocular Therapeutix
wet age-related macular degeneration
devices
OTX-TKI
Headline: 
Ocular Therapeutix doses first wet-AMD patient in implant trial
snippet: 

Ocular Therapeutix (NSDQ:OCUL) said today that it dosed the first patient in a study of its OTX-TKI tyrosine kinase inhibitor implant.

Do Not Allow Advertisers to Use My Personal information